1′-substituted carba-nucleoside analogs for antiviral treatment

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8853171
APP PUB NO 20130034521A1
SERIAL NO

13649511

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • GILEAD SCIENCES, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Butler, Thomas Redwood City, US 23 727
Cho, Aesop Mountain View, US 78 2917
Kim, Choung U San Carlos, US 138 4059
Parrish, Jay P Redwood City, US 36 1005
Saunders, Oliver L San Mateo, US 26 1481
Zhang, Lijun Los Altos Hills, US 155 1849

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 7, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00